OASIS-3 Subanalysis: Weight and Muscle Mass Outcomes With Elinzanetant

EP: 1.Impact of Menopause on Bone Health and Fracture Risk

EP: 2.Therapies for Vasomotor Symptoms and Their Effects on Bone Mineral Density

EP: 3.Neurokinin Therapies for VMS: MOAs and Potential Bone Health Implications

EP: 4.OASIS-3 Trial and Bone Mineral Density Subanalysis: Design, Methods, and End Points

EP: 5.BMD Biomarker Outcomes With Elinzanetant vs Placebo: Clinical Relevance and Implications

Now Viewing

EP: 6.OASIS-3 Subanalysis: Weight and Muscle Mass Outcomes With Elinzanetant

Video content above is prompted by the following:

The OASIS-3 subanalysis revealed favorable body composition changes with elinzanetant treatment, including weight decrease and reduced fat mass index. These findings are particularly significant given that postmenopausal women typically experience weight gain and increased fat accumulation, making these outcomes clinically relevant for patient quality of life.

Simultaneously, elinzanetant treatment was associated with increased lean mass index, suggesting preservation or enhancement of muscle mass. This combination of decreased fat mass and increased lean mass represents an ideal body composition profile that can contribute to overall metabolic health and bone strength.

The weight-neutral or weight-reducing effects of elinzanetant, combined with favorable muscle mass changes, make this treatment particularly attractive for postmenopausal women. These body composition benefits, alongside vasomotor symptom relief and potential bone health advantages, position elinzanetant as a comprehensive therapeutic option addressing multiple aspects of menopausal health management.